Anticoagulation in pregnancy complications

Hematology (United States)

Volumn 2014, Issue 1, 2014, Pages 393-399

  Middeldorp, Saskia ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT;

ADULT; BLOOD CLOTTING; CASE REPORT; CLINICAL TRIAL (TOPIC); COMPLICATION; DRUG EFFECTS; FEMALE; HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PRESCRIPTION; THROMBOPHILIA;

ADULT; ANTICOAGULANTS; BLOOD COAGULATION; CLINICAL TRIALS AS TOPIC; DRUG PRESCRIPTIONS; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; THROMBOPHILIA;

EID: 84925528647     PISSN: 15204391     EISSN: 15204383     Source Type: Journal    
DOI: 10.1182/asheducation-2014.1.393     Document Type: Article

References (43)

1. Middeldorp S. Thrombophilia and pregnancy complications: cause or association? J Thromb Haemost. 2007;5(Suppl 1):276-282.
2. Rodger MA, Paidas MJ, Mclintock C et al. Inherited thrombophilia and pregnancy complications revisited: association not proven causal and antithrombotic prophylaxis is experimental. Obstet Gynecol. 2008;112(2): 320-324.
3. de Jong PG, Goddijn M, Middeldorp S. Antithrombotic therapy for pregnancy loss. Hum Reprod Update. 2013;19(6):674-684.
4. Lewis G. Saving Mothers' Lives: reviewing maternal deaths to make motherhood safer - 2003-2005. In: CEMACH. The Seventh Report of the Confidential Enquiries into Maternal Deaths in the United Kingdom. London, UK: 2007.
5. Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients? Br J Haematol. 2008;143(5):321-335.
6. Miyakis S, Lockshin MD, Atsumi T et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306.
7. Quenby S, Mountfield S, Cartwright JE et al. Antiphospholipid antibodies prevent extravillous trophoblast differentiation. Fertil Steril. 2005; 83(3):691-698.
8. Redecha P, Franzke CW, Ruf W, Mackman N, Girardi G. Neutrophil activation by the tissue factor/Factor VIIa/PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest. 2008;118(10):3453-3461.
9. Isermann B, Sood R, Pawlinski R et al. The thrombomodulin-protein C system is essential for the maintenance of pregnancy. Nat Med. 2003;9(3):331-337.
10. Bose P, Black S, Kadyrov M et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol. 2005;192:23-30.
11. Robertson L, Wu O, Langhorne P et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol. 2006;132(2):171-196.
12. Abou-Nassar K, Carrier M, Ramsay T, Rodger MA. The association between antiphospholipid antibodies and placenta mediated complications: a systematic review and meta-analysis. Thromb Res. 2011;128(1): 77-85.
13. Rodger MA, Walker MC, Smith GN et al. Is thrombophilia associated with placenta-mediated pregnancy complications? A prospective cohort study. J Thromb Haemost. 2014;12(4):469-478.
14. Opatrny L, David M, Kahn SR, Shrier I, Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol. 2006;33(11):2214-2221.
15. Clark P, Walker ID, Govan L, Wu O, Greer IA. The GOAL study: a prospective examination of the impact of factor V Leiden and ABO(H) blood groups on haemorrhagic and thrombotic pregnancy outcomes. Br J Haematol. 2008;140(2):236-240.
16. Kahn SR, Platt R, McNamara H et al. Inherited thrombophilia and preeclampsia within a multicenter cohort: the Montreal Preeclampsia Study. Am J Obstet Gynecol. 2009;200(2):151-159.
17. Rodger MA, Carrier M, Le GG et al. Meta-analysis of low molecular weight heparin to prevent recurrent placenta-mediated pregnancy complications. Blood. 2014;123(6):822-828.
18. van Rijn BB, Hoeks LB, Bots ML, Franx A, Bruinse HW. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol. 2006;195(3):723-728.
19. Steegers EA, von DP, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet. 2010;376(9741):631-644.
20. Empson M, Lassere M, Craig JC, Scott JR. Prevention of recurrent miscarriage for women with antiphospholipid antibody or lupus anticoagulant. Cochrane Database Syst Rev. 2005;2:CD002859.
21. Carmona F, Font J, Azulay M et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am J Reprod Immunol. 2001;46(4):274-279.
22. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791-1798.
23. Henderson JT, Whitlock EP, O'Connor E et al. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force Aspirin for Prevention of Morbidity and Mortality From Preeclampsia. Ann Intern Med. 2014;160(10):695-703.
24. Bates SM, Greer IA, Middeldorp S et al. Venous thromboembolism, thrombophilia, antithrombotic therapy and pregnancy: ACCP evidencebased clinical practice guidelines (ninth edition). Chest. 2012;141(2 Suppl):e691S-e736S.
25. Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010;376(9751):1498-1509.
26. Clark P, Walker ID, Langhorne P et al. SPIN: the Scottish Pregnancy Intervention Study: a multicentre randomised controlled trial of low molecular weight heparin and low dose aspirin in women with recurrent miscarriage. Blood. 2010;115(21):4162-4167.
27. Kaandorp SP, Goddijn M, van der Post JA et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010;362(17):1586-1596.
28. de Jong PG, Kaandorp SP, Di Nisio M, Goddijn M, Middeldorp S. Aspirin or anticoagulants for treating recurrent miscarriage in women without antiphospholipid syndrome. Cochrane Database Syst Rev. 2014;7:CD004734.
29. Royal College of Obstetricians and Gynaecologists. The Investigation and Treatment of Couples with Recurrent First-trimester and Secondtrimester Miscarriage. Green-top Guideline No 17. London: Royal College of Obstetricians and Gynaecologists; 2011.
30. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies). BMJ. 1997;314(7076):253-257.
31. Ziakas PD, Pavlou M, Voulgarelis M. Heparin treatment in antiphospholipid syndrome with recurrent pregnancy loss: a systematic review and meta-analysis. Obstet Gynecol. 2010;115(6):1256-1262.
32. Alalaf S. Bemiparin versus low dose aspirin for management of recurrent early pregnancy losses due to antiphospholipd antibody syndrome. Arch Gynecol Obstet. 2012;285(3):641-647.
33. Visser J, Ulander VM, Helmerhorst FM et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomised multicentre trial. Thromb Haemost. 2011; 105(2):295-301.
34. Gris JC, Mercier E, Quere I et al. Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004;103(10):3695-3699.
35. Rodger M. Important publication missing key information. Blood. 2004;104(10):3413; author reply 3413-3414.
36. Mello G, Parretti E, Fatini C et al. Low-molecular-weight heparin lowers the recurrence rate of preeclampsia and restores the physiological vascular changes in angiotensin-converting enzyme DD women. Hypertension. 2005;45(1):86-91.
37. Rey E, Garneau P, David M et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009;7(1):58-64.
38. Gris JC, Chauleur C, Faillie JL et al. Enoxaparin for the secondary prevention of placental vascular complications in women with abruptio placentae: the pilot randomised controlled NOH-AP trial. Thromb Haemost. 2010;104(4):771-779.
39. Gris JC, Chauleur C, Molinari N et al. Addition of enoxaparin to aspirin for the secondary prevention of placental vascular complications in women with severe pre-eclampsia. The pilot randomised controlled NOH-PE trial. Thromb Haemost. 2011;106(6):1053-1061.
40. de Vries JI, van Pampus MG, Hague WM, Bezemer PD, Joosten JH. Low-Molecular-Weight Heparin Added to Aspirin in the Prevention of Recurrent Early-Onset Preeclampsia in women with Inheritable Thrombophilia: the FRUIT-RCT. J Thromb Haemost. 2012;10(1):64-72.
41. Martinelli I, Ruggenenti P, Cetin I et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012; 119(4):3269-3275.
42. Rodger MA, Hague WM, Kingdom J et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. Lancet. 2014. DOI 10.1016/S0140-6736(14)60793-5. [Epub ahead of print]
43. Schindewolf M, Gobst C, Kroll H et al. High incidence of heparininduced allergic delayed-type hypersensitivity reactions in pregnancy. J Allergy Clin Immunol. 2013;132(1):131-139.